Cargando…
Antiproliferative effects of somatostatin analogs in endocrine tumours
Somatostatin has been discovered as a somatotroph release inhibitory factor (SRIF), and it has been demonstrated that SRIF and its analogs can inhibit hormone secretion and control the neoplastic bulk of several endocrine tumours. In vitro studies have contributed to the current knowledge of the mec...
Autor principal: | Zatelli, Maria Chiara |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924708/ https://www.ncbi.nlm.nih.gov/pubmed/20948740 http://dx.doi.org/10.3410/M1-40 |
Ejemplares similares
-
Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis
por: Merola, Elettra, et al.
Publicado: (2017) -
Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
por: Weckbecker, G., et al.
Publicado: (1997) -
Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023) -
A review of the use of somatostatin analogs in oncology
por: Keskin, Ozge, et al.
Publicado: (2013) -
Somatostatin Analogs in Clinical Practice: A Review
por: Gomes-Porras, Mariana, et al.
Publicado: (2020)